Because no previous reports detailed the role of HMGB1 in the HCC chemotherapeutic response, our data suggest for the first time that a knockdown of HMGB1 restores the sensitivity to sorafenib in vitro in HepG2 cells and in vivo. This evidence concerns the gene HMGB1 and hepatocellular carcinoma.